Search by Drug Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y ZClinical Trials for TECFIDERA
- A Study of Dimethyl Fumarate (DMF) in Relapsing Forms of Multiple Sclerosis (RMS) Participants in China
- Comparative Bioavailability of BAFIERTAM™ (Monomethyl Fumarate) and Tecfidera® (Dimethyl Fumarate) in Healthy Subjects
- Long-Term Analysis of DImethyl Fumarate, to Slow the Growth of Areas of Geographic Atrophy
- Study to Compare GI Tolerability Following Oral Administration of Bafiertam™ or Tecfidera to Healthy Volunteers
- Study to Evaluate the Efficacy and Safety of Dimethyl Fumarate (Tecfidera) and Peginterferon Beta-1a (Plegridy) for the Treatment of Relapsing-Remitting Multiple Sclerosis in Pediatric Participants
- Fingolimod Versus Dimethyl-fumarate in Multiple Sclerosis
- Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
- A Tolerability Study of ALKS 8700 in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS) EVOLVE-MS-2
- Investigating Indirect Mechanism of Neuroprotection of Tecfidera® (Dimethyl Fumarate) in RRMS and Progressive Patients
- Dimethyl Fumarate (DMF) in Systemic Sclerosis-Associated Pulmonary Arterial Hypertension
- A Study of Efficacy and Safety of M2951 in Participants With Relapsing Multiple Sclerosis
- Dimethyl Fumarate Treatment of Primary Progressive Multiple Sclerosis
- Clinical Study to Compare the Efficacy and Safety of Ponesimod to Placebo in Subjects With Active Relapsing Multiple Sclerosis Who Are Treated With Dimethyl Fumarate (Tecfidera®)
- Monitoring of Patients Followed for a Multiple Sclerosis and Treated by Dimethyl-fumarate
- Patient Real-world Clinical, Neurological, Tolerability, and Safety Outcomes for Tecfidera® and Rebif®
- Dimethylfumarate (DMF) in Relapsed/Refractory CLL/SLL
- RItuximab Versus FUmarate in Newly Diagnosed Multiple Sclerosis.
- Assessment of Tecfidera® in Radiologically Isolated Syndrome (RIS)
- Impact of Tecfidera on Gut Microbiota
- Tecfidera Diffusion Tensor Imaging
- Pharmacokinetics of DMF and the Effects of DMF on Exploratory Biomarkers
- Mechanisms of Action of Dimethyl Fumarate (Tecfidera) in Relapsing MS
- Tecfidera and MRI for Brain Energy in MS
- Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012
- Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
- Tecfidera Lymphocyte Chart Review
- Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis
- Tecfidera and the Gut Microbiota
- Dimethyl Fumarate for Obstructive Sleep Apnea
- BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
- Tecfidera Slow-Titration Study
- Comparison of Rebif Compared to Tecifdera on Six-month Outcomes in Patients With Relapsing-remitting MS
- Study of Montelukast on Gastrointestinal Tolerability in Patients With Relapsing Forms of Multiple Sclerosis Receiving Tecfidera
- Study to Evaluate Whether a Medication Event Monitoring System (MEMS) Can Improve Adherence to Tecfidera Treatment in Multiple Sclerosis Patients.
- Effectiveness of DMF (Dimethyl Fumarate) and Its Impact on PROs (Patient Reported Outcomes) in Treatment-Naive or Suboptimal IFN (Interferon) or GA (Glatiramer Acetate) Responders With RRMS (ImPROve)
- Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Subjects With Relapsing-remitting Multiple Sclerosis (RRMS)
- Natalizumab as an Efficacy Switch in Participants With Relapsing Multiple Sclerosis After Failure on Other Therapies
- Restoring Glutathione Synthesis With Tecfidera: An in Vivo H-MRS Single-Arm Study at 7T in Patients With RR MS
- Pilot Study to Assess Dimethyl Fumarate Related GI Symptom Mitigation
- Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab)
- Gastrointestinal Tolerability Study Of Dimethyl Fumarate In Participants With Relapsing-Remitting Multiple Sclerosis In Germany
- RESOunD: REbif Satisfaction On Discontinuing Oral Dimethyl Fumarate
- Vaccination Response in Tecfidera-Treated Versus Interferon-Treated Participants With Relapsing Forms of Multiple Sclerosis.
- Phase 4 Study of Effect of Aspirin on Flushing in Dimethyl Fumarate-Treated Participants With Relapsing-Remitting Multiple Sclerosis
- Study to Evaluate Fatigue in Participants With Relapsing Remitting Multiple Sclerosis When Treated With Dimethyl Fumarate
- Dimethyl Fumarate (DMF) Observational Study
- A Study Evaluating the Effectiveness of Tecfidera (Dimethyl Fumarate) on Multiple Sclerosis (MS) Disease Activity and Patient-Reported Outcomes
- BG00012 Regional Absorption Study
- PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily
- Biogen Multiple Sclerosis Pregnancy Exposure Registry
- Effectiveness of DMF and Its Impact on PROs in Suboptimal GA Responders With RMS
- Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States
- An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
- Estriol Treatment in Multiple Sclerosis (MS): Effect on Cognition
- BG00012 Phase 2 Combination Study in Participants With Multiple Sclerosis
- BG00012 Monotherapy Safety and Efficacy Extension Study in Multiple Sclerosis (MS)
- Stem Cell Therapy for Patients With Multiple Sclerosis Failing Alternate Approved Therapy- A Randomized Study
Clinical trials list
click for details